When was Actithera founded?

Actithera was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Actithera located?

Actithera is headquartered in Cambridge, United States.

Who is the current CEO of Actithera?

Andreas Goutopoulos of Actithera. They have also founded 1 company.

How many employees does Actithera have?

As of Mar 31, 2026, the latest employee count at Actithera is 28.

Is Actithera a funded company?

Actithera is a funded company, having raised a total of $80.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 01, 2023.

When was the latest funding round of Actithera?

Actithera's latest funding was a $***** Series A round on Jul 09, 2025, with participation from 9 investors.

Where does Actithera rank among its competitors?

Actithera ranks 501st amongst 2486 active competitors, of which 866 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Actithera, which secured $75.5M in Jul, 2025.

Who are the top competitors of Actithera?

Actithera's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Actithera secured the most recent funding round in July, 2025.

Actithera - 2026 Company Profile, Team, Funding & Competitors

Company Details

Actithera is a radiopharmaceutical company developing novel radiotherapeutics for cancer treatment. Leveraging a unique medicinal chemistry approach, the company aims to discover and develop theranostics with prolonged tumor retention. With a strong focus on precision medicine, Actithera is poised to revolutionize the treatment of cancer through targeted radiotherapy.

Website: actithera.com
Email ID: *****@actithera.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Cambridge, United States

Stage

Series A

Total Funding

$80.8M in 2 rounds

Latest Funding Round

Series A, Jul 09, 2025, $*****

Investors

M Ventures & 8 more

Ranked

501^st among 2486 active competitors

Employee Count

28 as on Mar 31, 2026

Similar Companies

Molecular Partners & 90 more

View Actithera's full profile

Actithera is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ACTITHERA, INC. CIN: 4490934 , United States, Active	Apr 09, 2021	-	-	-

Actithera has raised a total funding of $80.8M over 2 rounds. Its first funding round was on Apr 01, 2023. Its latest funding round was a Series A round on Jul 09, 2025 for $*****. 9 investors participated in its latest round. Actithera has 9 institutional investors.

Here is the list of recent funding rounds of Actithera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 09, 2025	6532236	Series A	5365424	9626829	5442705	6922603
Apr 01, 2023	7759530	Seed	9785951	5126937	M Ventures	Arkin

Access funding benchmarks and valuations. Sign up today!

View details of Actithera's funding rounds and investors

The founders of Actithera is Andreas Goutopoulos. Andreas Goutopoulos is the CEO of Actithera.

Here are the details of Actithera's key team members:

Andreas Goutopoulos: Co-Founder & CEO of Actithera.
Contact Info: 1 email address

View details of Actithera's Founder profiles and Board Members

Actithera's employee count trend

Actithera has 28 employees as of Mar 26. Here is Actithera's employee count trend over the years:

Uncover Actithera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Actithera include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Actithera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
9th	Molecular Partners 2004, Zurich (Switzerland), Public	Developer of therapeutic solutions for treating multiple diseases	$59.9M	Index Ventures, Endeavour Vision & 4 others	71/100
10th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
501st	Actithera 2021, Cambridge (United States), Series A	Radiopharmaceutical company developing novel radiotherapeutics for the treatment of cancer through its unique medicinal chemistry platform	$80.8M	4Bio Capital, Hadean Ventures & 7 others	50/100